Qiagen (NYSE:QGEN) Downgraded to Hold Rating by Barclays

Barclays downgraded shares of Qiagen (NYSE:QGEN) from a strong-buy rating to a hold rating in a research note published on Tuesday, MarketBeat reports. Barclays currently has $44.00 target price on the stock.

A number of other research firms have also recently issued reports on QGEN. Deutsche Bank Aktiengesellschaft raised shares of Qiagen from a “hold” rating to a “buy” rating and set a $54.00 price target on the stock in a research note on Friday, March 13th. Zacks Research cut shares of Qiagen from a “hold” rating to a “strong sell” rating in a research note on Monday, March 9th. UBS Group set a $52.00 target price on shares of Qiagen in a research note on Monday, February 9th. Wall Street Zen lowered Qiagen from a “buy” rating to a “hold” rating in a report on Saturday, March 28th. Finally, Robert W. Baird set a $53.00 price target on Qiagen in a report on Friday, February 6th. Four research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $53.64.

Qiagen Stock Performance

QGEN opened at $41.75 on Tuesday. Qiagen has a 12-month low of $38.79 and a 12-month high of $57.81. The company has a current ratio of 3.90, a quick ratio of 3.31 and a debt-to-equity ratio of 0.44. The firm has a market capitalization of $8.60 billion, a PE ratio of 20.71, a P/E/G ratio of 2.17 and a beta of 0.79. The firm has a 50 day moving average of $44.65 and a two-hundred day moving average of $47.61.

Qiagen (NYSE:QGEN) last posted its earnings results on Wednesday, February 4th. The company reported $0.62 earnings per share for the quarter, beating the consensus estimate of $0.61 by $0.01. The firm had revenue of $540.42 million during the quarter, compared to analyst estimates of $528.53 million. Qiagen had a net margin of 20.33% and a return on equity of 14.56%. The business’s quarterly revenue was up 3.6% on a year-over-year basis. During the same period in the previous year, the firm earned $0.61 EPS. Qiagen has set its FY 2026 guidance at 2.500- EPS and its Q1 2026 guidance at 0.540- EPS. On average, analysts anticipate that Qiagen will post 2.26 EPS for the current year.

Institutional Trading of Qiagen

A number of large investors have recently made changes to their positions in QGEN. United Services Automobile Association purchased a new stake in shares of Qiagen during the first quarter worth approximately $239,000. Prudential Financial Inc. boosted its holdings in Qiagen by 74.9% in the second quarter. Prudential Financial Inc. now owns 8,873 shares of the company’s stock valued at $426,000 after purchasing an additional 3,799 shares in the last quarter. Invesco Ltd. boosted its holdings in Qiagen by 123.7% in the second quarter. Invesco Ltd. now owns 1,006,025 shares of the company’s stock valued at $48,350,000 after purchasing an additional 556,387 shares in the last quarter. EverSource Wealth Advisors LLC boosted its holdings in shares of Qiagen by 226.4% in the second quarter. EverSource Wealth Advisors LLC now owns 2,598 shares of the company’s stock valued at $125,000 after acquiring an additional 1,802 shares during the period. Finally, First Trust Advisors LP acquired a new stake in shares of Qiagen in the second quarter valued at approximately $3,639,000. 70.00% of the stock is currently owned by hedge funds and other institutional investors.

Qiagen Company Profile

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library?preparation kits and proteomics solutions.